About

About Pandorum Technologies Pandorum is a platform technology company in the field of Tissue Engineering and Regenerative Medicine, operating out of US and India, currently in clinical translation stage (ongoing cGMP manufacturing of novel exosome based therapeutics) for skin and cornea regeneration. #Platform: At Pandorum we have developed a proprietary technology platform that allows us to develop exosome based nanotherapy derived from human Mesenchymal stem cell (MSC), with tunable cargo molecules and tailored properties- such as anti-inflammatory, anti-fibrotic, neurogenesis, pro/ anti- angiogenesis etc., to promote functional regeneration of human tissues, such as, cornea, skin, liver, lung and nervous system. #Product(s): Our flagship assets are K-Exo and D-Exo based advanced therapeutics, optimized for human surface tissues cornea and skin regeneration, respectively. Both are currently in the clinical manufacturing process by AGC Biologics (production site in Milan- approved by both USFDA and EMA), derived from clinical grade human MSCs (highly defined, with existing USFDA Drug Master file). a. The ‘liquid cornea' (Kuragenx), is a first-in-class combination product containing K-exo for cornea regeneration, delivered via Hyaluronic Acid based biopolymer matrix for sustained release. Kuragenx has demonstrated promising results in the preclinical studies to treat advanced neurotrophic keratitis (NK) and has been awarded Orphan Drug Designation by the U.S. Food and Drug Administration (FDA). b. The D-Exo is a best-in-class Pharma grade exosome developed for dermal regeneration with enhanced re-epithelialization, anti-anti-inflammatory, anti-fibrotic properties, well suited for both aesthetics as well as clinical dermatology applications. Given the proprietary priming of MSCs and modular tunable bioprocess, our pharma grade D-Exo can be produced with superior yield and potency with significant folds of enhancement in cost vs benefit, in comparison to the currently marketed cosmeceutical grade exosomes. # Assorted publications and media coverages: 1. Kuragel: A biomimetic hydrogel scaffold designed to promote corneal regeneration. ISCIENCE (2024). DOI: https://doi.org/10.1016/j.isci.2024.109641 2. Chemical (Alkali) Burn-Induced Neurotrophic Keratitis Model in New Zealand Rabbit Investigated by Medical Clinical Readouts and In Vivo Confocal Microscopy (IVCM). Cells 12 (2023). DOI:10.3390/cells13050379 3. In Vitro Assay to Examine the Function of Tears on Corneal Epithelial Cells. Bio-Protocol. 13(xx) (2023). DOI:10.21769/BioProtoc.4910 4. Biopolymeric corneal lenticules by digital light processing based bioprinting: a dynamic substitute for corneal transplant. Biomedical Materials, 19 (2024). DOI:10.1088/1748-605X/ad3312 5. Revolutionizing regenerative medicine with engineered biomaterials. Biopharma Dealmakers, Nature Research, 2023. https://www.nature.com/articles/d43747-023-00098-w 6. How India is building its 3D bioprinting industry. Nature India: https://www.nature.com/articles/d44151-024-00008-8 7. Entrepreneurship World Cup by MISK foundation- global finalists: Pandorum origin story - Pandorum: https://youtu.be/DLcPy2F2Rws?si=WvlVp_KK9zDCFcoX 8. Pandorum's approach to AI powered regenerative medicine by WIPRO: https://www.wipro.com/newsroom/press-releases/2022/wipro-and-pandorum-partner-to-accelerate-regenerative-medicine-wit-ai